FTISADTSK
FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) [1].
Product Specifications
CAS Number
1431957-73-1
UNSPSC
12352209
Target
Drug Metabolite
Type
Peptides
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ftisadtsk.html
Purity
99.02
Solubility
10 mM in H2O
Smiles
O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](N)CC1=CC=CC=C1)=O)=O
Molecular Formula
C42H68N10O16
Molecular Weight
969.05
References & Citations
[1]Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88 (3) :1871-1877.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15327036 1 Vial
Lentiviral human GUF1 shRNA (UAS) - Lentiviral human GUF1 shRNA (UAS, GFP) (100)
Sign In for Pricing
View Details 